With this detailed understanding of her cancer's characteristics, the treatment commenced in August 2021 with osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), which was chosen based on its efficacy in targeting EGFR-mutated non-small cell lung cancer [6]. Here, EGFR is linked to non-small cell lung carcinoma.